Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an announcement.
Arovella Therapeutics Ltd announced that its CEO, Dr. Michael Baker, will present at the ASX SMIDcaps Conference, highlighting the company’s advancements in iNKT cell therapy for cancer treatment. This presentation underscores Arovella’s strategic efforts to strengthen its industry position and engage stakeholders by showcasing its innovative approaches to cancer therapy.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumors. Its lead product, ALA-101, consists of CAR19-iNKT cells targeting CD19, an antigen found on numerous cancer types. The company is also expanding into solid tumor treatment through CLDN18.2-targeting technology and incorporating IL-12-TM technology into its programs.
Average Trading Volume: 1,274,031
Technical Sentiment Signal: Sell
Current Market Cap: A$105.3M
For a thorough assessment of ALA stock, go to TipRanks’ Stock Analysis page.